Mersana Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Mersana Therapeutics wird ein Gewinn- und Umsatzwachstum von 19.4% bzw. 24.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 19.2% pro Jahr wachsen soll.

Wichtige Informationen

19.4%

Wachstumsrate der Gewinne

19.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	24.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	05 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Jun 19

Mersana Therapeutics: On Hold While Waiting For Any Positive News

May 15

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Apr 25

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Feb 27

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Jan 11

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Oct 14

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Jun 09

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Feb 22

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Jun 05

Mersana Therapeutics EPS misses by $0.11, misses on revenue

May 10

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mar 23

Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Jan 29

Bain Capital discloses 4.8% stake in Mersana Therapeutics

Jan 13

Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst

Jan 11

Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study

Jan 05

Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?

Dec 08

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:MRSN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	31	-112	-88	-89	5
12/31/2025	33	-97	-79	-78	8
12/31/2024	40	-78	-65	-60	9
3/31/2024	38	-135	-174	-173	N/A
12/31/2023	37	-172	-171	-169	N/A
9/30/2023	41	-197	-191	-188	N/A
6/30/2023	39	-215	-90	-87	N/A
3/31/2023	32	-213	-73	-70	N/A
12/31/2022	27	-204	-52	-49	N/A
9/30/2022	12	-208	-42	-41	N/A
6/30/2022	6	-194	-132	-131	N/A
3/31/2022	2	-183	-122	-121	N/A
12/31/2021	0	-170	-141	-140	N/A
9/30/2021	0	-150	-116	-115	N/A
6/30/2021	0	-127	-100	-99	N/A
3/31/2021	1	-106	-81	-80	N/A
12/31/2020	1	-88	-75	-75	N/A
9/30/2020	1	-75	-70	-70	N/A
6/30/2020	2	-70	-66	-66	N/A
3/31/2020	1	-67	-65	-64	N/A
12/31/2019	42	-28	-68	-68	N/A
9/30/2019	43	-34	-72	-71	N/A
6/30/2019	45	-35	-66	-65	N/A
3/31/2019	49	-30	-64	-63	N/A
12/31/2018	11	-64	-57	-55	N/A
9/30/2018	13	-56	-52	-50	N/A
6/30/2018	17	-46	-53	-51	N/A
3/31/2018	16	-43	-50	-49	N/A
12/31/2017	18	-39	N/A	-43	N/A
9/30/2017	26	-23	N/A	-19	N/A
6/30/2017	23	-22	N/A	-12	N/A
3/31/2017	26	-16	N/A	-11	N/A
12/31/2016	25	-14	N/A	32	N/A
12/31/2015	10	-16	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MRSN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MRSN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MRSN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MRSNDie Einnahmen des Unternehmens (24.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: MRSNDie Einnahmen des Unternehmens (24.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MRSN in 3 Jahren voraussichtlich hoch sein wird

Mersana Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$1.72 loss

Price target decreased by 31% to US$10.50

Price target decreased by 11% to US$15.00

Consensus revenue estimates increase by 20%

Consensus revenue estimates increase by 725%

Price target decreased to US$17.75

Recent updates

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Mersana Therapeutics: On Hold While Waiting For Any Positive News

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.52 loss in 1Q 2023)

Mersana Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Mersana Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Mersana Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Mersana Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Director notifies of intention to sell stock

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Mersana Therapeutics, Inc. Announces Business Updates

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Mersana Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.72 loss

Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Price target decreased by 31% to US$10.50

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Price target decreased by 11% to US$15.00

Full year 2022 earnings released: US$2.18 loss per share (vs US$2.41 loss in FY 2021)

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Mersana Therapeutics, Inc. Initiates Expansion Portion of Upgrade-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

Mersana Therapeutics, Inc. Announces Initiation of Phase 1 Trial of XMT -2056 in Her2-Expressing Tumors

President exercised options and sold US$100k worth of stock

Consensus revenue estimates increase by 20%

Chief Science & Technology Officer exercised options to buy US$230k worth of stock.

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Mersana Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

Mersana Therapeutics Inc. Announces Launch of Oncology Facets

Mersana gains as FDA grants fast track status for breast cancer drug

Mersana Therapeutics, Inc. Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers

Consensus revenue estimates increase by 725%

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.75

Consensus revenue estimates increase by 12%

Mersana Therapeutics, Inc. Announces FDA Grant of Orphan Drug Designation to Xmt-2056 for the Treatment of Gastric Cancer

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Mersana Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

Consensus revenue estimates increase by 93%

Consensus revenue estimates increase by 17%

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Taking The Measure Of Mersana Therapeutics

Chief Science & Technology Officer exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.33 loss in 3Q 2020)

Price target decreased to US$24.00

Price target decreased to US$24.00

Chief Manufacturing Officer Michael Kaufman has left the company

Consensus revenue estimates fall to US$256.2k

First half 2021 earnings released: US$1.09 loss per share (vs US$0.68 loss in 1H 2020)

President exercised options and sold US$513k worth of stock

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Chief Science & Technology Officer notifies of intention to sell stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.35 loss in 1Q 2020)

Consensus forecasts updated